FILTER

Refine your search with the following facets to narrow down your results.

8 Current news of AVI BioPharma

Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses

23-Aug-2010 - New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental ...

antibodies biosafety biotechnology +10

AVI BioPharma Announces $24 Million Direct Equity Placement

25-Jan-2005 - AVI BioPharma, Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 8 million shares of its common stock at $3.00 per share in a direct equity placement for gross proceeds to the company of $24 million. Investors also will receive ...

AVI BioPharma Appoints Vice President of Cardiology

21-Jan-2005 - AVI BioPharma, Inc. announced that Joseph B. Horn has joined the company as vice president of cardiology. Horn joins AVI from Cook, Inc., where he most recently served as vice president of international sales and clinical services. Horn brings a range of industry experience in medical devices ...

cardiology clinical trials medical devices +1

AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus

02-Nov-2004 - AVI BioPharma, Inc. , and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) announced positive results from experiments testing the effect of AVI's NeuGene® antisense drugs against Ebola virus (EBOV) in vivo. The NeuGene compounds targeted several EBOV genes. These ...

Ebola food genes +4

AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes

13-Sep-2004 - AVI BioPharma, Inc. (Nasdaq: AVII), today announced it presented data on its NeuGene® antisense approach to transplant acceptance at the 20th International Congress of the Transplantation Society, held in Vienna, Austria, Sept. 5-10, 2004. The presentation, titled "Antisense Inhibition of cFLIP ...

apoptosis bone marrow immune cells +2

AVI BioPharma Announces Dengue Virus Collaboration With CDC

25-Aug-2004 - AVI BioPharma, Inc. announced it has signed a Cooperative Research and Development Agreement (CRADA) with the Centers for Disease Control and Prevention (CDC). The two-year agreement provides for further testing of AVI's NEUGENE(R) antisense therapeutics, which have been shown to be highly ...

infectious diseases viruses

AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents

12-Aug-2004 - Portland. AVI BioPharma, Inc. announced it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The five-year agreement provides for testing of AVI's NeuGene® antisense therapeutics against several ...

bacteria infectious diseases viruses

AVI BioPharma's NeuGene Antisense Shows Inhibition of Dengue Virus

02-Jun-2004 - PORTLAND, Ore. - AVI BioPharma, Inc., presented results of a study showing inhibition of dengue virus with its NeuGene® antisense compounds at the Seventh International Symposium on Positive-Strand RNA Viruses held in San Francisco May 27- June 1. Dengue virus is a single-stranded RNA virus that ...

cell cultures dengue fever hemorrhagic fevers +10